Answers are grounded in this paper and cite their sources.
This perspective discussed the available evidence on the involvement of mTOR pathway in antiphospholipid syndrome (APS), from the aspects of endothelial cells, platelets, monocytes and anti-phospholipid antibodies (PLs), which may lead to future therapeutic applications of mTOR inhibition in APS.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: